<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04779892</url>
  </required_header>
  <id_info>
    <org_study_id>CMAB008HV-I</org_study_id>
    <nct_id>NCT04779892</nct_id>
  </id_info>
  <brief_title>The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety</brief_title>
  <official_title>The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taizhou Mabtech Pharmaceutical Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taizhou Mabtech Pharmaceutical Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 1, Randomized, Double-blind, Parallel group, Sing-dose study to compare the&#xD;
      Pharmacokinetics and Safety of CMAB008 and Remicade in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Actual">June 15, 2020</completion_date>
  <primary_completion_date type="Actual">June 15, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Biological: CMAB008 Biological: Remicade</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 1680 Hours After the Single Infusion of CMAB008/Remicade</measure>
    <time_frame>up to 1680 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration of Infliximab After the Single Infusion of CMAB008/Remicade</measure>
    <time_frame>up to 1680 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Concentration of Infliximab After the Single Infusion of CMAB008/Remicade</measure>
    <time_frame>up to 1680 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Zero (0) Hours Extrapolated to infinite time After the Single Infusion of CMAB008/Remicade</measure>
    <time_frame>up to 1680 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Frequency of AE/SAE Within the Whole Time of the Study</measure>
    <time_frame>up to 1680 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients in Whom Bind or Neutralizing Antibodies to Infliximab Were Detected</measure>
    <time_frame>up to 1680 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>CMAB008</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Remicade</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>100mg/vial</description>
    <arm_group_label>CMAB008</arm_group_label>
    <arm_group_label>Remicade</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy subject (male) between the ages of 18 and 45 years.&#xD;
&#xD;
          -  Subject with a body weight of ≥50 kg and ≤ 80 kg and a BMI between 19.0~26.0 kg/m2&#xD;
             (both inclusive);&#xD;
&#xD;
          -  Healthy as determined by pre-study medical history, physical examination, vital signs&#xD;
             and 12-lead electrocardiogram;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those who have surgered 4 weeks before signing the informed consent;&#xD;
&#xD;
          -  Those with mental, respiratory, cardiovascular, digestive, urinary, reproductive,&#xD;
             skeletal and motor, blood, endocrine, nervous and other system diseases, or those with&#xD;
             any previous immune diseases;&#xD;
&#xD;
          -  Those who have received any drug treatment (including prescription drugs,&#xD;
             over-the-counter drugs, biological products, Traditional Chinese medicine, vitamins,&#xD;
             dietary supplements, etc.) and health care products within 4 weeks before signing the&#xD;
             informed consent;&#xD;
&#xD;
          -  Those who accepted biological drugs within 6 months before signing the informed&#xD;
             consent, or accepted the TNF monoconal antibody drugs;&#xD;
&#xD;
          -  Any one of HIV antibody, HBsAg, HBeAg, HBcAg, HCV antibody and Treponema pallidum&#xD;
             antibody is positive;&#xD;
&#xD;
          -  Either T cell immunospot test (T-SPOT) or antinuclear antibody is positive;&#xD;
&#xD;
          -  Those who have infected within 30 days before administration, or serious infection&#xD;
             associated with hospitalisation and/or which required inrravenous antibiotics within 3&#xD;
             months before administration.&#xD;
&#xD;
          -  Vaccinated within 30 months before signing the informed conset, or plan to vaccinate&#xD;
             during the trail;&#xD;
&#xD;
          -  Those who have used soft drugs within 3 months prior to signing the informed consent&#xD;
             or hard drugs within 1 year prior to the trail; those who have positive drug abuse&#xD;
             test results;&#xD;
&#xD;
          -  Those who drinking too much tea, coffee and/or caffeinated beverages (more than 8&#xD;
             cups, 250ml per cup) every day;&#xD;
&#xD;
          -  Those who have a blood donation history of 400 ml within 3 months, or 200 ml within 1&#xD;
             month;&#xD;
&#xD;
          -  Those who have a history of drug or food allergy, or are known to be allergic to any&#xD;
             component of the test drug or latex, etc.&#xD;
&#xD;
          -  Those who are addicted to smoking or smoke more than 10 cigarettes per day on average&#xD;
             within 6 months before signing the informed consent;&#xD;
&#xD;
          -  Alcoholics or regular drinkers within 3 months before the trail, i.e. those who drink&#xD;
             more than 14 units of alcohol per week (14 bottles of 360 ml beer or 630 ml spirits&#xD;
             with 40% alcohol), or whose alcohol breath test is positive;&#xD;
&#xD;
          -  Those who plan to donate sperm within 6 months after the adminstration of the test&#xD;
             drug;&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai Xuhui Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

